// App-Quantinova.ai

P621 : Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn’s disease patients: results from the EVOLVE study

Researchers

Presenter

  • B Bressler

Principal Investigators

  • G Mantzaris

  • M Silverberg

  • P Zezos

  • D Stein

  • C Colby

  • T Lissoos

  • C Lopez

  • A Natsios

  • G Radulescu

  • H Patel

  • D Demuth

  • A Yarur

Medical Centers

  • St Pauls Hospital, Vancouver, BC, Canada

  • Evangelismos Hospital, Athens, Greece

  • IBD Center, Mount Sinai Hospital, Toronto, Canada

  • Evidera, London, UK

  • Evidera, California, USA

  • Takeda USA Inc., Chicago, USA

  • Takeda SA Inc., Athens, Greece

  • Takeda Canada Inc., Toronto, Canada

  • Takeda Pharmaceuticals International, Deerfield, IL

  • Takeda International–UK Branch, London, UK

  • The Medical College of Wisconsin, Milwaukee, WI

Locations

  • Canada

  • Greece

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • Human albumin

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved